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Valproic acid autoinduction: a case‑based
review
Sean Bennett1 and Mujeeb U. Shad2,3,4*

Abstract
Although valproic acid (VPA) induces the metabolism of multiple other drugs, the clinical reports of VPA autoinduction are rare. A comprehensive literature search yielded only one published case series, which provided the rationale
to conduct a review of the published cases along with a new case of VPA autoinduction. Although there may be
myriad of reasons for lack of published cases of VPA autoinduction, potential underreporting may be one of the core
reasons. Lack of understanding into the highly complex metabolism of VPA may also make it difficult to recognize and
report VPA autoinduction. However, it is important to mention that in addition to autoinduction increased elimination
of VPA may be mediated by several pharmacokinetic (PK) factors, such as drug interactions, genetic polymorphisms
of metabolic enzymes, and protein displacement reactions. As VPA is metabolized by multiple metabolic pathways,
the risk for drug interactions is relatively high. There is also a growing evidence for high genetic inducibility of some
enzymes involved in VPA metabolism. Protein displacement reactions with VPA increase the biologically active and
readily metabolizable free fraction and pose a diagnostic challenge as they are usually not requested by most clinicians. Thus, monitoring of free fraction with total VPA levels may prevent clinically serious outcomes and optimize
VPA treatment in clinically challenging patients. This case-based review compares the clinical data from three published cases and a new case of VPA autoinduction to enhance clinicians’ awareness of this relatively rare but clinically
relevant phenomenon along with a discussion of potential underlying mechanisms.
Keywords: Valproic, Acid, Autoinduction, Case-based, Review
Introduction
Valproic acid (VPA) is one of the oldest and most frequently prescribed drugs for epilepsy, bipolar disorder,
and migraine prophylaxis (Peterson and Naunton 2005).
This is one of the few psychotropic drugs that have
fairly well-defined therapeutic levels that range from
50 to 100 µg/mL for epilepsy and 80 to 125 µg/mL for
bipolar disorder (Patsalos et al. 2008). These therapeutic levels are usually achieved at VPA doses well under
4000 mg/day. However, VPA doses required to achieve
recommended therapeutic levels vary significantly
across patients, which could be due to its highly complex metabolism. Valproic acid is metabolized by both
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phase-I and phase-II enzyme systems as well as fatty acid
β-oxidation. Although rarely reported, VPA autoinduction is a clinically-significant phenomenon in a high-risk
patient population with bipolar disorder and epilepsy
as sub-therapeutic VPA levels may result in clinically
serious outcomes, such as suicide and seizures, respectively. A comprehensive literature search yielded only
one published case series reporting three cases of VPA
autoinduction (Jackson et al. 2015), which could be due
to potential under-reporting, lack of understanding into
the complex nature of VPA metabolism as well as lesser
recognition of drugs as inducers than inhibitors (de Leon
2015a, b). Finding the current case of VPA autoinduction
provided us the rationale to conduct a review of the published cases along with the new case in order to analyze
and compare clinical data and increase clinicians’ awareness into VPA autoinduction. This case-based review also
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provided an opportunity to discuss various pharmacokinetic mechanisms underlying VPA autoinduction to minimize seriously adverse outcomes and optimize clinical
outcomes in challenging patients.

Methods
The current case of the bipolar patient hospitalized for
inpatient treatment was identified after he required unusually high dose of VPA to achieve therapeutic levels. A
comprehensive literature search yielded only one case
series comprised of three patients who required unusually high VA doses to be effective. The current case was
added to the three cases of VPA autoinduction in the
published case series to conduct a case-based review. The
literature search was conducted in MEDLINE/PubMed,
EMBASE, CINAHL, PsychINFO without any restrictions. The following search terms were employed for this
search: ((‘valproic acid’ OR ‘valproate’ OR ‘VPA’) AND
(‘autoinduction’ OR ‘auto-induction’ OR ‘induction’ OR
‘inducibility’)). A total of 13 records were found of which
four records included both search terms and one record
documenting VPA autoinduction in three patients in a
case series. All VPA levels were trough levels obtained at
the steady state, including the current case. The concentration/dose (C/D) ratio for the current case was calculated using the same methods and rationale as described
in the published case series (Jackson et al. 2015). Briefly,
the VPA level was divided by the VPA dose and multiplied by 1000 to make the ratio numerically clear.
Results
As can be seen from the Table 1, all reviewed cases were
Caucasian males, with a mean age (SD) of 55.25 ± 14.17,
receiving a formulation of VPA for various diagnoses,
including bipolar disorder, schizophrenia, tuberous sclerosis, and traumatic brain injury. However, the clinical
data for three published cases were collected over several
years of inpatient treatment as compared to clinical data
for the current subject over a much shorter hospital stay
of 22 days. The current patient was admitted for severe
traumatic brain injury, methamphetamine use, and bipolar symptoms, such as racing thoughts, lack of sleep,
increased energy, and pressured speech, but without any
other psychiatric or neurological disorders. VPA levels
for all cases were trough levels obtained at a steady state
using the same clinical laboratory. However, in contrast
to several years of data collection for the three published
cases, the VPA levels in the current case were obtained
only over 22 days. The normal therapeutic ratio of VPA
C/D ratio × 1000 ranged between 112 and 132 µg/mL.
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Brief case histories of previously published cases
Case 1

A 34-year old Caucasian male with treatment-refractory schizophrenia developed a seizure disorder before
he was hospitalized with four antiepileptic medications:
carbamazepine, phenytoin, diazepam, and VPA, but all
with subtherapeutic levels. It took several months to
titrate off these medications, except VPA. The seizures
were not adequately controlled until the VPA dose
was increased to 5250 mg/day to achieve therapeutic
concentrations. However, VPA had to be switched to
divalproex sodium (DVPS) after the patient began to
complain about the bad taste of the VPA concentrate.
This switch led to an unexpected valproate intoxication
despite the absence of any other medication changes.
Case 2

This patient was a 66-year-old Caucasian male with a
long history of bipolar disorder and substance use disorder. He was admitted to a psychiatric hospital for
bipolar symptoms and psychosis, which was managed
by starting 1000 mg/day DVPS. However, he continued
to display rapid, pressured speech and flight of ideas, in
addition to increased levels of energy, which required
a gradual increase in DVPS dose to 4000 mg/day to
have an antimanic response with a therapeutic level of
around 70 μg/mL.
Case 3

This patient was a middle-aged Caucasian male with
tuberous sclerosis manifested as a seizure disorder and
mental retardation. He had been in inpatient treatment
at a state psychiatric hospital for about 22 years before
he started to have complications from tuberous sclerosis, including a right renal tumor, worsening episodes
of ataxia and confusion, and a giant cell astrocytoma.
Thus, the patient required a progressive increase in
the DVPS dose from a baseline dose of 3375 mg/day
to a therapeutic dose of 10,500 mg/day. This dose was
maintained until it was found that the patient’s physical
deterioration was due to astrocytoma, resulting in discontinuation of all medications except phenytoin and a
reduction in DVPS from a dose of 10,500 to 7000 mg/
day.
Current case

A 51-year old Caucasian male with past psychiatric
history of bipolar disorder and methamphetamine use
disorder, who was consulted by Consult-Liaison (C-L)
psychiatry following a three-week inpatient surgical
hospitalization after the wreckage of his recreational
vehicle while under the influence of methamphetamine.
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66

70

Case 2*

Case 3*

New Case 51

Bipolar disorder
Methamphetamine use
disorder
Recent Traumatic Brain
Injury

Tuberous Sclerosis

Bipolar Disorder
Substance Use disorder

22 days

> 4 years

VPA

DVPS

DVPS

DVPS

< 1 year

8 weeks

VPA

> 3 years

5000

10,500

4000

2000

5250

98.8

10

67
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19.8

12

17

39

17

7

137

10

7

44

Hospital Duration Formulation VPA dose VPA C/D
No. of
(mg/day) level ratio × 1000a VPA
(μg/
Levels
mL)

Significantly lower C/D ratio than
the normal range between 112
and 132 µg/mL, suggesting
faster VPA metabolism

Higher C/D ratio with DVPS than
VPA in case 1, suggesting significantly slower DVPS metabolism
than VPA

Significantly lower C/D ratio than
the normal range between 112
and 132 µg/mL, suggesting
faster VPA metabolism

Comments

18.6 ± 2.9,
range = 13–20

Similar C/D ratio to case 1 & 2,
suggesting similar rate of autoinduction with VPA

8 ± 3.5, range = 3–20 Lowest C/D ratio of all cases, suggesting robust autoinduction
with DVPS

25 ± 5.6,
range = 17–33

39 ± 6.3,
range = 28–48

15 ± 2.6,
range = 10–21

Mean C/D
ratio × 1000:
mean ± SD, range#

a

#

C/D ratio × 1000; Calculated from the last final VPA dose and the level at that dose

Mean C/D ratio × 1000: mean ± SD, range; Calculated from the total number of VPA levels during hospital duration

*Reference = Jackson et al. (2015) VPA: valproic acid; DVPS: divalproex sodium; C/D = Mean concentration/dose ratio (therapeutic range between 112 to 132 µg/mL); Number of VPA levels drawn over total hospitalization

90

Schizophrenia
Seizure disorder

34

Case 1*

85

Age Wt. (kg) Diagnosis

Cases

Table 1 Relationship between age, weight, valproic acid (VPA) formulation, daily VPA dose, average VPA levels, and concentration/dose (C/D) ratio × 1000 mean ± SD and range
across cases
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Injuries sustained resulted in a skull fracture and
intracranial hemorrhage, requiring neurosurgery.
Recovery was then complicated by ongoing aggression and agitated delirium, for which CL psychiatry
was consulted. The initial efforts were to reduce the
use of as-needed medications, discontinue deliriogenic
medications, and transition the patient to high dose IV
haloperidol to manage aggression. A dose of 156 mg
IV haloperidol over 24 h was administered but had to
be discontinued due to prolonged QTc interval, with
the highest QTc value reaching 560 ms and a return to
420 ms following haloperidol’s discontinuation. Three
different second-generation antipsychotic medications,
benzodiazepines, and opiate pain medications failed to
adequately manage patient’s aggression, At this time, a
collaborative, multi-team decision was made to intubate the patient and perform a medication washout due
to refractory, severe, and persistent agitated delirium.
Eventually, valproic acid (Depakene®), quetiapine and
risperidone were introduced to manage aggressive
and impulsive behavior in a setting of traumatic brain
injury (TBI) with a history of possible underlying bipolar mania. Following extubation and washout, the delirium resolved. The patient was alert and able to fully
orient and converse; however, he remained agitated
and aggressive with staff, demanding to leave against
medical advice (AMA). In the meanwhile, repeated
VPA dose titrations were required to achieve therapeutic trough levels of 98.8 µg/mL at the steady state
at an unusually high total dose of 5000 mg/day. Eventually, the patient stabilized and was discharged on day
22 of hospitalization. Of note, risperidone was discontinued after the 18th day of VPA initiation to reduce
polypharmacy.

Discussion
As can be seen from the Table 1, similar to the prior
cases, the new case (case 4) required aggressive titration of VPA dose to achieve therapeutic VPA levels
required for bipolar disorder (80–125 µg/mL) (Peterson and Naunton 2005). Although it took several years
for the published cases to attribute the need for unusually high VPA doses to autoinduction (Jackson et al.
2015), it took only a few days to do so for the current
case due to the valuable clinical information provided by
the published case series. Since VPA has a highly complex metabolism, an initial discussion of different PK
factors involved in VPA autoinduction may be relevant
here. About 40% of VPA is metabolized by multiple isoforms of a phase-II enzyme, uridine diphosphate glucuronyl transferase (UGT1A6, UGT1A9, and UGT2B7),
(Li et al. 2004; Patsalos and Perucca 2003); while 30%
is metabolized via β-oxidation, and the rest by multiple
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phase-I cytochrome P450 (CYP) enzymes (i.e., CYP2A6,
CYP2C9, and CYP2C19) (Ghodke-Puranik et al. 2013;
Perucca et al. 2006). It is interesting to note that two of
the three UGT isoforms (i.e., UGT2B7, UGT1A9) and
one of the CYP enzymes (CYP2C9) that metabolize VPA
are actually inhibited by VPA (Morris et al. 2000). In this
context, inhibition of UGT2B7 is well-documented to
elevate lamotrigine levels when co-administered with
VPA (Wang et al. 2016) by 2–3 folds (Morris et al. 2000)
increasing the risk for dose-dependent life threatening
skin rashes associated with lamotrigine. This is despite
some animal studies reporting increased VPA glucuronidation (Fisher et al. 1991) and β-oxidation (Fisher et al.
1991; McLaughlin et al. 2000) but with long-term use
of VPA. Another study (McLaughlin et al. 2000) found
at least 3 weeks delay in mild VPA autoinduction with a
low-dose VPA mediated by the β-oxidation but not UGT.
The delayed enzyme induction probably does not explain
the relatively fast autoinduction observed in reviewed
cases. However, there are many other PK factors that can
also alter VPA plasma levels, including drug interactions,
protein displacement reactions, genetic polymorphisms,
and activation of nuclear receptors.
In terms of drug interactions, VPA is known to elevate plasma levels of only a few drugs, most notably
lamotrigine (Wang et al. 2016; Morris et al. 2000). However, VPA is more frequently reported to increase the
metabolism of multiple co-administered drugs, such as
aripiprazole (Citrome et al. 2005), clozapine (Cerveny
et al. 2007; Finley and Warner 1994; Longo and Salzman
1995; Diaz et al. 2014), norclozapine, felbamate (Hooper
et al. 1996), irinotecan (Jong et al. 2007), and olanzapine
(Bergemann et al. 2006; Haslemo et al. 2012). The relatively rare reports of VPA autoinduction suggest that the
VPA-induced induced enzymes may not be relevant in
VPA metabolism. Regardless, the high level of long-term
polypharmacy in the published cases was not observed
in the current subject, who was only treated with two
concomitantly administered medications (i.e., 4 mg/day
of risperidone & 950 mg/day of quetiapine). Both these
medications were co-administered at the same dose for
18 out of 22 days of hospitalization, and none has been
reported to significantly interact with VPA. Most of
the other concomitant drugs in the published cases are
not known to significantly alter VPA metabolism with
the only exception of phenytoin in case 3. Phenytoin is
a robust inducer for enzymes, including UGT and may
have contributed to the VPA autoinduction (Zaccara
et al. 2014).
The protein displacement reactions may also enhance
VPA metabolism, which may sometimes be confused
with autoinduction. Valproic acid is highly proteinbound drug, which can saturate protein binding sites at
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levels ≥ 50 µg/mL (Jackson et al. 2015), thereby increasing the biologically active and readily metabolizable free
fraction (Dutta et al. 2007; Kodama et al. 2001). A similar increase in free fraction may occur if VPA is displaced
by more potent protein-bound drugs, such as ibuprofen
(Lana et al. 2016a, 2016b). Thus, dose-dependent protein saturation is one of the many non-inducing factors
that can magnify VPA autoinduction. Valproic acid, in
turn, may displace phenytoin, which is a lesser protein
bound drug (Lai and Huang 1993; Perucca et al. 1980),
thereby decreasing its plasma levels (Wen et al. 2001).
This decrease is often counterbalanced by an increase in
phenytoin levels via VPA-induced inhibition of CYP2C9
that metabolizes phenytoin (Franco and Perucca 2015).
This observation is consistent with unchanged phenytoin levels in case 3. Since albumin is the plasma protein
that binds VPA (Hermida and Tutor 2005; VandenBerg
et al. 2017), any change in albumin levels may also alter
VPA levels. Thus, an increase in VPA free fraction has
been reported in patients with hypoalbuminemia due to
acute medical stress and renal or liver dysfunction (Hermida and Tutor 2005; VandenBerg et al. 2017). However,
increased free fraction from protein saturation is clinically different from that reported with hypoalbuminemia. Unlike protein saturation, any increase in VPA dose
in patients with hypoalbuminemia may overwhelm the
metabolic pathways to effectively eliminate significantly
elevated levels of biologically active free fraction, thus
increasing the risk for VPA toxicity in the absence of a
notable increase in total VPA levels (Hermida and Tutor
2005). This underscores the need to obtain free fraction
levels in addition to the total VPA levels to guide critical VPA dose adjustments in clinically challenging cases
(Maat et al. 2011). A simple subtraction of free fraction
from the total VPA levels may help determine proteinbound VPA levels to distinguish between protein saturation and hypoalbuminemia.
Genetic polymorphisms in enzymes that metabolize
VPA may explain the high inter-individual variability
in VPA levels (Methaneethorn 2018; Ding et al. 2015).
The most significant inducible variants for UGT1A6 are
541A > G and 552A > C), which have been associated
with increased metabolism of VPA in children (Guo
et al. 2012; Hung et al. 2011; Wang and Zhou 2016).
A relatively recent metanalysis supported the inducibility of the two UGT1A6 variants in other age groups
as well (Kim and Kim 2019). Another study reported a
third inducible UGT1A6 variant (i.e., 19T > G) as well
as a CYP2C9 variant in VPA-treated patients with
severe traumatic brain injury (Sun et al. 2017). Tanner and Tyndale (2017) found a second inducible CYP
enzyme, 2A6 to further contribute to the significant
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inter-individual variation in VPA levels (Tanner and
Tyndale 2017). Inducible variants of UGT2B7 (i.e.,
G211T and C161T) were also reported to require VPA
dose adjustments for therapeutic effects in a metanalysis (Wang et al. 2018). Since UGT variance was
not assessed in the reviewed cases, the effects of UGT
polymorphism(s) on VPA autoinduction cannot be
assessed. Nevertheless, genetic testing for CYP2C9 and
CYP2C19 that metabolize VPA (Jiang et al. 2009) ruled
out any dysfunctional alleles for these enzymes in the
published case series (Jackson et al. 2015).
Another potential mechanism for VPA autoinduction
could be the activation of a nuclear receptor, peroxisome proliferator-activated (Kallen 2004; Lampen et al.
1999; Werling et al. 2001), which has been associated
with induction of UGT enzymes (Fisher et al. 1991; Luci
et al. 2006). However, it is unlikely that activation of other
nuclear receptors associated with increased expression of
CYP3A4 and P-glycoprotein (P-gp) (Cerveny et al. 2007)
could have contributed to the VPA autoinduction as VPA
is not a substrate for either of the two. This is in contrast
to another antiepileptic drug, carbamazepine, which is
associated with robust autoinduction as it increases the
expression of CYP3A4 and P-gp, for which it is a substrate (Lutz et al. 2018).
This review has several limitations including the retrospective nature of the clinical data, the lack of VPA
free fraction level monitoring, the significant difference
in hospital duration between the current and published
cases, the lack of post-discharge follow-up and VPA level
monitoring for the current case. Nevertheless, this review
underscores the clinical significance of not only monitoring total VPA levels, but also the free fraction, to facilitate
diagnosis and management of VPA autoinduction.

Conclusion
The findings from this review are based on a retrospective analysis of only four cases and should be interpreted
with caution. However, the clinicians should consider
VPA autoinduction in patients with unusually low plasma
levels despite conventional VPA doses. It appears that
VPA autoinduction is a relatively rare phenomenon
probably because of multiple PK factors that may result
in or contribute to VPA autoinduction, most notably
drug interactions, protein displacement reactions, and
genetic polymorphisms in enzymes metabolizing VPA.
Until future research addresses the complexities of VPA
metabolism, the most logical way to deal with clinically
challenging cases is to obtain both total and free fraction
VPA levels for safe and effective VPA dose adjustments.
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